Anti-Mullerian hormone level may predict rate of bone loss d
Researchers analyzed data from the Study of Women’s Health Across the Nation (SWAN), a prospective cohort study of women aged 42 to 52 years who were premenopausal or early perimenopausal at baseline and were not prescribed hormone therapy. Bone mineral density measurements and fasting blood draws were collected at baseline and follow-up visits at intervals of 1 to 2 years.

Women with 50% less serum AMH had an additional 0.37% loss in lumbar spine BMD and 0.27% loss in femoral neck BMD from baseline to 2 to 3 years follow-up. AMH levels may help predict how much ongoing or future bone loss a woman in menopause transition may experience and can help providers with implementing interventions to slow the BMD decline.